Post by CareValidate

Peptides are having a moment: consumer interest is up 20x year-over-year, and by July 23–24 the conversation gets a lot more concrete. That's when the FDA's Pharmacy Compounding Advisory Committee meets to review seven peptides — BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and Emideltide — for possible return to the 503A Bulks List. Here's the part most headlines will skip: a favorable recommendation isn't an approval, and it doesn't make anything legally compoundable on its own. We broke down what a PCAC meeting actually is, what the three-category system means for compounders, where CareValidate stands, and what's already live in our formulary today (NAD+, Sermorelin, GHK-Cu, PT-141, Glutathione) regardless of how this meeting goes. Read the full breakdown --> https://lnkd.in/gpWfkk4b